Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (36): 6757-6761.doi: 10.3969/j.issn.1673-8225.2011.36.025

Previous Articles     Next Articles

Adoptive immunotherapy for leukemia in mice after autologous bone marrow mixed with H-2 haploidentical allogeneic bone marrow transplantation

Wang Cun-bang, Bai Hai, Xi Rui, Zhang Qian, Zhou Jin-mao, Zhao Qiang, Pan Yao-zhu   

  1. Hematology Center, General Hospital of Lanzhou Military Area Command of Chinese PLA, Lanzhou  730050, Gansu Province, China
  • Received:2011-01-31 Revised:2011-02-22 Online:2011-09-03 Published:2011-09-03
  • About author:Wang Cun-bang☆, Doctor, Associate chief physician, Master’s supervisor, Hematology Center, General Hospital of Lanzhou Military Area Command of Chinese PLA, Lanzhou 730050, Gansu Province, China wangcunbang98＠163.com
  • Supported by:

    the "Eleventh Five-Year" Outstanding Talents Foundation of the Chinese PLA, No. 06J005*; Medical Research Foundation of Lanzhou Military Area Command of Chinese PLA, No. LXH-2007006*

PDF

303

Abstract:

BACKGROUND: Auto hemopoietic stem cell transplantation (Auto-HSCT) has a high relapse rate in acute leukemia; allo-HSCT has a high incidence of transplant-related mortality. It may increase curative effect when leukemia patients are administered adoptive immunotherapy post mixed-HSCT.
OBJECTIVE: To explore the curative effect of using donor lymphocyte infusion combined with interleukin-2 (DLI+IL-2) after autologous bone marrow mixed with H-2 haploidentical allogeneic bone marrow transplantation (MBMT) in mice with leukemia.
METHODS: Leukemia models were prepared with Balb/c mice which were irradiated 3 Gy by linear accelerator and injected K562 (GFP+/NeoR+) or K562 (GFP-/NeoR-) cells 5×105 into caudal vein and divided into leukemia model group, irradiated leukemia model group, MBMT group, and autologous bone marrow transplantation (ABMT) group. 6 Gy irradiation was performed after 7 days; the mice were treated with ABMT or MBMT respectively. Mice of MBMT group mixed with 1/10 of H-2 haploidentical allogeneic bone marrow cells underwent IL-2 or combination of DLI treatment. Peripheral blood and bone marrow cell morphous of mice were examined; cell subsets, GFP and NeoR gene in peripheral blood, and liver, spleen homogenate cells, and NeoR gene were detected after 4 weeks.
RESULTS AND CONCLUSION: All of mice in leukemia model group died of bone marrow hematopoietic failure within 20 days; mice in irradiated leukemia model group died of hematopoietic failure within 14 days. Varying amounts of non-leukemic of mice survived for more than 28 days between ABMT group and MBMT group. UsingIL-2 treatment after MBMT and ABMT can promote long term disease free survival of mice with leukemia, and which combined with DLI can further improve long term disease free survival of mice with leukemia.

CLC Number: